Diagenode

About Diagenode

Diagenode, now operating as Hologic Diagenode, is a Belgian life sciences company specializing in epigenomics profiling services, molecular diagnostics and sample preparation tools for next‑generation sequencing, proteomics and epigenetics research. Founded in 2003 in Liège/Seraing, it has built a comprehensive portfolio of instruments such as the Bioruptor sonicators, high‑quality reagent kits and extensively validated antibodies that standardize critical workflows including chromatin shearing, ChIP‑seq, ATAC‑seq and DNA methylation assays. These products are used globally by academic laboratories, biotechs, pharmaceutical companies and clinical research organizations to explore gene regulation and uncover novel biomarkers. ​ Beyond tools, Diagenode offers full‑stack epigenomics and RNA‑seq services, covering experimental design, wet‑lab execution and advanced bioinformatics analysis. Its service offering spans chromatin immunoprecipitation sequencing (ChIP‑seq), ATAC‑seq, whole‑genome and reduced representation bisulfite sequencing (WGBS, RRBS), and a range of RNA‑sequencing approaches, including small RNA and CATS‑based low‑input workflows. This integrated model enables customers to outsource complex projects such as genome‑wide mapping of histone marks, methylation profiling and transcriptome characterization, accelerating discovery while ensuring data quality and reproducibility. ​ ​ In parallel, Diagenode has built a CE‑marked molecular diagnostics menu of more than 30 real‑time PCR assays targeting infectious agents involved in sexually transmitted infections, respiratory diseases, meningitis and gastroenteritis, among others. These assays, combined with the company’s epigenetics expertise, position it at the interface of research and clinical application, supporting both fundamental science and translational diagnostics development. Hologic’s 2021 acquisition of Diagenode, valuing the company at approximately $159 million on annual revenues above $30 million, reflects the strategic importance of its technologies and European footprint in the broader molecular diagnostics market. ​